The proposed work is to generate broadly-protective influenza virus vaccines. The basic experimental approach that we will use to accomplish the goal of vaccine generation is divided into two phases.
Aim 1 involves characterization of human and murine monoclonal antibodies with broad protective activity against hemagglutinins of distinct influenza virus strains. Efforts will be made to determine the precise region of binding of these broadly-protective antibodies on the hemagglutinin molecule.
Aim 2 of this work will involve the design and production of novel vaccine constructs that focus immunity towards those epitopes determined to mediate broad protection. We will construct a set of novel immunogens: several will be based on conserved, continuous, polypeptidic regions of the hemagglutinin, others are based on conformational, discontinuous moieties or on chimeric hemagglutinins. The vaccination strategies will involve the use of DNA, recombinantly purified protein or purified (chimeric) virus. In collaboration with Projects 2 and 3, the vaccine constructs will be optimized by use of complementary adjuvant preparations and will be evaluated for efficacy in both mouse and in ferret models of disease.

Public Health Relevance

Present influenza virus vaccines have to be newly manufactured every year because the circulating influenza virus strains are continuously changing. We are attempting to design novel universal influenza virus vaccines which would be cross-protective against different strains and thus last longer, avoiding the necessity of annual revaccinations;this will be done by first identifying cross-protective monoclonal antibodies (directed against the viral hemagglutinin) and the precise epitopes/sequences they recognize. These epitopes will then be used to guide the design of vaccine constructs which induce cross-protective immune responses against many different influenza virus variants.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI097092-02
Application #
8528831
Study Section
Special Emphasis Panel (ZAI1-RB-M)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
2
Fiscal Year
2013
Total Cost
$299,093
Indirect Cost
$68,848
Name
Icahn School of Medicine at Mount Sinai
Department
Type
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Guo, Hailong; Baker, Steven F; Martínez-Sobrido, Luis et al. (2014) Induction of CD8 T cell heterologous protection by a single dose of single-cycle infectious influenza virus. J Virol 88:12006-16
Krammer, Florian; Margine, Irina; Hai, Rong et al. (2014) H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge. J Virol 88:2340-3
Krammer, Florian; Palese, Peter (2014) Universal influenza virus vaccines: need for clinical trials. Nat Immunol 15:3-5
Krammer, Florian; Hai, Rong; Yondola, Mark et al. (2014) Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets. J Virol 88:3432-42
Schotsaert, Michael; García-Sastre, Adolfo (2014) Influenza vaccines: a moving interdisciplinary field. Viruses 6:3809-26
Miller, Matthew S; Palese, Peter (2014) Peering into the crystal ball: influenza pandemics and vaccine efficacy. Cell 157:294-9
DiLillo, David J; Tan, Gene S; Palese, Peter et al. (2014) Broadly neutralizing hemagglutinin stalk-specific antibodies require Fc?R interactions for protection against influenza virus in vivo. Nat Med 20:143-51
Heaton, Nicholas S; Langlois, Ryan A; Sachs, David et al. (2014) Long-term survival of influenza virus infected club cells drives immunopathology. J Exp Med 211:1707-14
Cowan, Michelle; Chon, W James; Desai, Amishi et al. (2014) Impact of immunosuppression on recall immune responses to influenza vaccination in stable renal transplant recipients. Transplantation 97:846-53
Krammer, Florian; Albrecht, Randy A; Tan, Gene S et al. (2014) Divergent H7 immunogens offer protection from H7N9 virus challenge. J Virol 88:3976-85

Showing the most recent 10 out of 22 publications